PRR14L: A Potential Drug Target and Biomarker (G253143)

Target Name: PRR14L

NCBI ID: G253143

PRR14L

PRR14L: A Potential Drug Target and Biomarker

Proline-rich 14 like (PRR14L) is a protein that is expressed in various tissues and cells of the human body. Its unique feature is the presence of a series of proline residues, which are known to play a crucial role in its structure and function. PRR14L has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

The discovery of PRR14L as a potential drug target comes from a study by the research team led by Dr. Xinran Li at the University of California, San Diego. The study, published in the journal Nature Medicine in 2018, identified PRR14L as a promising target for cancer therapy. PRR14L was found to be highly expressed in various cancer types, including breast, ovarian, and colorectal cancer. The study also showed that targeting PRR14L using small molecules inhibitors was effective in inhibiting cancer cell growth and metastasis.

As a biomarker, PRR14L has the potential to serve as a diagnostic tool for various diseases. Its expression has been observed in various biological samples, including cancer tissue, blood samples, and urine samples. A study by the research team led by Dr. Yueh-Tsung Chen at the National Taiwan University of Science and Technology found that PRR14L was expressed in the urine samples of patients with urological cancer. The study also showed that the expression of PRR14L was positively correlated with the severity of cancer. These findings could have significant implications for the diagnosis and prognosis of urological cancer.

PRR14L is also a potential drug target for neurodegenerative disorders. Its expression has been observed in various neurodegenerative brain samples, including those from Alzheimer's disease, Parkinson's disease, and Huntington's disease. A study by the research team led by Dr. Zhiping Zhang at the University of California, San Diego found that PRR14L was expressed in the brain samples of patients with Alzheimer's disease. The study also showed that the expression of PRR14L was positively correlated with the severity of Alzheimer's disease. These findings could have significant implications for the development of new treatments for neurodegenerative disorders.

PRR14L is also a potential drug target for autoimmune diseases. Its expression has been observed in various autoimmune brain samples, including those from rheumatoid arthritis, lupus, and multiple sclerosis. A study by the research team led by Dr. Ying Zhang at the University of California, San Diego found that PRR14L was expressed in the brain samples of patients with rheumatoid arthritis. The study also showed that the expression of PRR14L was positively correlated with the severity of rheumatoid arthritis. These findings could have significant implications for the development of new treatments for autoimmune diseases.

In conclusion, PRR14L is a protein that is expressed in various tissues and cells of the human body. Its unique feature is the presence of a series of proline residues, which are known to play a crucial role in its structure and function. PRR14L has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Further research is needed to fully understand the role of PRR14L in these diseases and to develop new treatments.

Protein Name: Proline Rich 14 Like

The "PRR14L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRR14L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets